Similarly, ACEi/ARB therapy, where indicated, and SGLT‐2i therapies were independently associated with lower mortality, corroborating findings from large‐scale trials such as EMPA‐REG OUTCOME and CANVAS, which demonstrated the benefits of SGLT‐2 inhibitors in reducing cardiovascular events and mortality in patients with diabetes and established cardiovascular disease [26, 27]. Here, SLC5A2 is linked to cardiovascular disorder.